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Abstract
Background: Vasopressin (AVP) and terlipressin (TP) have been used as last-line therapy in refractory shock in
children. However, the efficacy and safety profiles of AVP and TP have not been determined in pediatric refractory
shock of different origins. We aimed to assess the efficacy and safety of the addition of AVP/TP therapy in pediatric
refractory shock of all causes compared to conventional therapy with fluid resuscitation and vasopressor and
inotropic therapy.
Methods: We conducted a systematic review, meta-analysis, and trial sequential analysis (TSA) comparing AVP and
TP to conventional therapy. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched up to
February 2016. The systematic review included all reports of AVP/TP use in the pediatric population. Reports of
clinical trials were pooled using random-effects models and TSA. Main outcomes were mortality and tissue
ischemia.
Results: Three randomized controlled trials and five “before-and-after clinical” trials (without comparator) met the
inclusion criteria. Among 224 neonates and children (aged 0 to 18 years) with refractory shock, 152 received
therapy with AVP or TP. Pooled analyses showed no association between AVP/TP treatment and mortality (relative
risk (RR),1.19; 95% confidence interval (CI), 0.71–2.00), length of stay in the pediatric intensive care unit (PICU) (mean
difference (MD), –3.58 days; 95% CI, –9.05 to 1.83), and tissue ischemia (RR, 1.48; 95% CI, 0.47–4.62). In TSA, no
significant effect on mortality and risk for developing tissue ischemia was observed with AVP/TP therapy.
Conclusion: Our results emphasize the lack of observed benefit for AVP/TP in terms of mortality and length of stay
in the PICU, and suggest an increased risk for ischemic events. Our TSA suggests that further large studies are
necessary to demonstrate and establish benefits of AVP/TP in children.
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Background
Hemodynamic shock is a leading cause of morbidity and
mortality in the pediatric population worldwide [1]. A
delay in treating shock may result in irreversible organ
damage [2, 3]. Morbidity from shock may include renal
failure, disseminated intravascular coagulation (DIC),
and death [1–3]. Early goal-directed therapy is targeted
at maintaining and restoring an adequate ventilation and
circulation within the first hour of shock onset [4–6].
Aggressive fluid resuscitation is the first line of therapy
for shock [7]. Thereafter, hemodynamic support is
achieved with vasopressors and inotropes [5, 7]. How-
ever, reduced vasoconstrictor sensitivity to vasopressors
in shock can lead to vasodilation, severe hypotension,
and vasoparalysis [8]. There is, therefore, a pressing need
for agents which target other pathways involved in the
development of shock.
In the past decade, arginine-vasopressin (AVP) has
emerged as a potentially useful therapy for refractory
shock [9]. AVP acts on V1 receptors located on vascular
smooth muscle leading to an increase in mean arterial
pressure (MAP). Patients with shock exhibit inappropri-
ately low circulating AVP concentrations [7, 8, 10]. From
a biologic perspective, the basic rationale behind the
addition of AVP/TP in refractory shock is the depletion
of endovascular AVP in states of shock [11]. Further-
more, AVP/terlipressin (TP) may contribute to MAP ele-
vation in the refractory shock state since vascular
smooth muscle shows a decreased ability to contract,
and the hypotension may be refractory to standard cat-
echolamine vasopressor therapy [12].
AVP and TP administration in states of shock may be
beneficial in improving cardiovascular parameters, such
as MAP and heart rate (HR) [13, 14]. AVP/TP may also
be used in vasodilatory shock following cardiopulmonary
bypass [15].
There is a paucity of data regarding the outcomes of
the use of AVP/TP in refractory shock in children. A
Cochrane review from 2013, which aimed to assess the
efficacy and safety of AVP in neonates with refractory
shock, did not find sufficient evidence to recommend or
refute the use of AVP [16]. We therefore sought to con-
duct a systematic review, meta-analysis, and trial se-
quential analysis (TSA) to evaluate the efficacy and
safety of AVP/TP in critically ill neonates and children
with refractory shock of different origins compared to
conventional therapy with fluid resuscitation, vasopres-
sor, and inotropic therapy.
Methods
Data sources and searches
This systematic review followed the Preferred Reporting
Items for Systematic Reviews and Meta-analysis (PRISMA
2009) framework guidelines and the review protocol was
registered at the PROSPERO registry of systematic reviews
on February 2016 (registry number: CRD 42016035872)
[17, 18]. The systematic review was performed using
MEDLINE, EMBASE, and Cochrane through February
2016 to identify all published randomized controlled trials
(RCTs), prospective clinical trials (“before and after”,
without a comparator group), cohort studies, case-
control studies, and case series involving the treatment/
comparison of AVP or TP (in addition to conventional
therapy) in pediatric refractory shock (of septic, vasodila-
tory, or mixed origin) to conventional therapy. Relevant
studies were identified using the following search terms:
“vasopressin”, “terlipressin”, “shock”, “septic”, “refractory”,
“hypotension”, “vasodilatory”, “mixed”, “children”, “neo-
nates”. We subsequently searched and evaluated published
systematic reviews, online resources, conference abstracts,
clinicaltrials.gov, and expert opinion to ensure identifica-
tion of all published and unpublished studies. No language
or date restrictions were applied to the search. No ap-
proval from the Institutional Review Board was required.
Study selection and data extraction
The studies were identified through a search by one re-
viewer (RM), and the abstracts were independently
screened by two reviewers (RM and BHR). Disagree-
ments were resolved by consensus and/or referral to a
third reviewer (IM). The full text of the resulting refer-
ences was then retrieved by one reviewer (RM). The pri-
mary endpoints of this analysis were mortality outcomes
(30-day mortality in RCTs or mortality during/by end of
trial in non-RCTs) and tissue ischemia (new onset or
worsening of existing condition). Secondary outcomes
included hemodynamic indices, vasoactive score, and the
length of stay in the pediatric intensive care unit (PICU).
Selection criteria
We applied the following screening criteria to determine
qualitative eligibility for inclusion in the meta-analysis:
prospective clinical studies (RCTs and prospective “before
and after ” clinical trials, without comparator group) of
children aged 0 to 18 years and in refractory shock, which
compared AVP/TP (in addition to conventional therapy)
to conventional therapy and reported on mortality, mor-
bidity, at least two hemodynamic indices, and adverse ef-
fects, and which met 1b and 1c levels of evidence of the
Oxford Centre for Evidence-based Medicine (CEBM)
levels of evidence 2011 [19]. We excluded studies of AVP/
TP for other indications, or with no full-text access. Retro-
spective and prospective observational studies and case
reports were included in the systematic review only.
Quality assessment and risk of bias
The methodological quality of the studies included was
assessed using the CEBM levels of evidence 2011 [19].
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Risk of bias was assessed according to the Cochrane
Collaboration methodology [20].
Data synthesis
We conducted a meta-analysis to pool the results of
trials comparing conventional therapy only with conven-
tional therapy plus AVP/TP using Comprehensive Meta-
analysis (CMA 3.0). For TSA, the TSA program v.0.9
beta was used (http://www.ctu.dk/tsa/downloads.aspx).
For bias risk assessment we used Review Manager
(RevMan), Version 5.3. Copenhagen (The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014).
The primary comparison themes were mortality and tis-
sue ischemia. Secondary comparison themes included
vasoactive score, the length of stay in the PICU, and
hemodynamic measures. For studies reporting only the
interquartile range (IQR) for continuous measure out-
comes, we assumed that the mean and median were
equal, and calculated the standard deviation (SD) from
IQR by dividing the IQR by 1.35 [21]. To calculate the
change in continuous hemodynamic measures we esti-
mated the standard deviation from the pooled variance
of each measure. Heterogeneity was assessed using the
I2 statistic. Values of 25%, 50%, and 75% for I2 repre-
sented low, medium, and high heterogeneity, respectively
[22]. We used random-effects models to pool results.
We calculated risk ratios (RRs) for dichotomous out-
comes when including only RCTs in the analysis. Event
rates (ERs) were calculated for dichotomous outcomes
including RCTs and “before-and-after clinical” trials
(without comparator). Event rates are a measure of how
often an event occurred in a group [23], and are mea-
sures of the occurrence of an event for each participant
over the time they were observed. Pooled event rates
from the "before and after" clinical trials can provide an
estimate of the expected rates of these events in the set-
tings evaluated; however, they do not provide a direct es-
timate of the relative effect of the intervention compared
to a control. The mean difference (MD) was calculated
for continuous outcomes, with their corresponding 95%
confidence intervals (CIs). Statistical significance was de-
fined using a two-sided α of 0.05, and interpretations of
clinical significance emphasized CIs.
Trial sequential analysis
Meta-analyses may result in type I errors owing to an in-
creased risk of random error when sparse data are ana-
lyzed [24]. TSA allows for controlling the p value when
scarce data exist and clear conclusions cannot be drawn
[25, 26]. TSA allows the quantification of the required
sample size for determining the effect under study while
adjusting the threshold for statistical significance [25, 26].
The threshold for reaching statistical significance adjusts
the CIs and reduces type I errors. When the cumulative
z-curve crosses the threshold boundaries, one may con-
clude that a sufficient level of evidence for the inter-
vention effect has been reached and no further trials
are needed. If the z-curve does not cross any of the
boundaries, evidence to reach a conclusion is insuffi-
cient [25]. We used TSA adjusted random-effects
models to pool results from RCTs for primary out-
comes. We conducted two- and one-sided TSA to
maintain a risk of 5% for type I error and a power of
80%. We used the estimated function to calculate the
required information size (IS). We calculated 95% CIs
adjusted for repetitive testing.
Results
Trial flow
Our search yielded 140 relevant titles. Initial screening
led to the exclusion of 18 duplicate records and 72 re-
cords that did not meet inclusion criteria. The remaining
50 publications were retrieved for full-text review.
Twenty-two publications were excluded based on inclu-
sion criteria, leaving 28 studies. Twenty studies were ob-
servational and were included in the systematic review
only (Additional file 1: Table S1), leaving eight clinical
publications for meta-analysis. The selection process is
illustrated in Fig. 1.
Characteristics and quality of clinical studies included in
the meta-analysis
The studies included in the analysis are detailed in
Table 1. In total, 224 children received AVP/TP. In all
reports, conventional therapy with volume resuscitation
and vasopressors/inotropes were given prior to the initi-
ation of AVP/TP (excluding one study which included
volume resuscitation or dopamine) [27]. Three RCTs
[27–29] and five clinical trials [30–34] met the 1b and
1c level criteria of the CEBM [19], and two RCTs had a
low risk for bias (Additional file 2: Figure S1) [27, 29].
The studies included evaluated the effect of AVP/TP in
the pediatric population over a relatively wide range of
ages, and the majority of the studies were not restricted
to shock arising from a specific mechanism.
Meta-analysis
Mortality
The addition of AVP/TP to vasopressor/inotropic ther-
apy in refractory shock had no significant effect on mor-
tality. Analysis of RCTs resulted in a non-significant
difference in risk compared to conventional treatment,
with a RR of 1.19 with low heterogeneity (95% CI, 0.71–
2.00; I2 = 28%) (Fig. 2). The mortality rate among pa-
tients treated with AVP/TP in the clinical trials was high,
with a pooled ER of 0.49 (95% CI, 0.37–0.61) (Fig. 3). In
TSA, the boundary for futility was not crossed, and no
effect on mortality was observed; the estimated IS to
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reach the futility boundaries was 392 randomized pa-
tients (Fig. 4).
Tissue ischemia
The addition of AVP/TP to vasopressor/inotropic
therapy in refractory shock had no significant effect
on the risk for developing tissue ischemia. Analysis of
RCTs resulted in a non-significant difference in risk
compared to conventional treatment, with a RR of
1.48 with low heterogeneity (95% CI, 0.47–4.62; I2 = 0%)
(Fig. 5). The tissue ischemia rate among patients
treated with AVP/TP in the clinical trials was consid-
erable, with a pooled ER of 0.16 (95% CI, 0.08–0.28)
(Additional file 3: Figure S2). In TSA, the boundary
for futility was not crossed, and no effect on tissue is-
chemia was observed; the estimated IS to reach the futility
boundaries was 231 randomized patients (Additional
file 4: Figure S3).
Vasoactive score
The addition of AVP/TP in refractory shock resulted in
a significant decrease in the vasoactive score compared
to standard therapy, with a pooled MD of –14.13
units and low heterogeneity (95% CI, –20.61 to –7.66;
I2 = 38.25%) (Additional file 5: Figure S4).
Mean arterial pressure
The addition of AVP/TP in refractory shock resulted in
a significant increase in the MAP, with a pooled MD of
12.34 mmHg and high heterogeneity (95% CI, 6.38–18.3;
I2 = 93%) (Additional file 6: Figure S5).
Heart rate
The addition of AVP/TP in refractory shock resulted in
a significant decrease in the HR, with a pooled MD of –
12.25 beats per minute and intermediate heterogeneity
(95% CI, –18.96 to –5.55; I2 = 67%) (Additional file 7:
Figure S6).
Length of stay in the PICU
The addition of AVP/TP in refractory shock did not re-
sult in a significant decrease in the length of stay, with a
pooled MD of –3.58 days (reduction) and intermedi-
ate heterogeneity (95% CI, –9.05 to 1.83; I2 = 54%)
(Additional file 8: Figure S7).
Discussion
In this meta-analysis, no significant difference in mortality
risk was found between AVP/TP and conventional treat-
ment for refractory shock in the pediatric population. Fur-
thermore, after applying TSA, the non-significant effect
Fig. 1 Publication selection and search process
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on mortality outcomes remained; however, a large number
of randomized patients would be required to reach the fu-
tility boundary. Although no significant difference in tis-
sue ischemia risk was found, when applying TSA we
found a trend towards a higher risk for tissue ischemia.
AVP/TP treatment did significantly improve hemodynamic
indices, with a significant reduction in the vasoactive
score, HR, and an increase in MAP.
Our meta-analysis indicates that AVP/TP therapy is
ineffective in reducing mortality in refractory shock in
the pediatric population. Our results demonstrate that
mortality rates among patients treated with AVP/TP in
the clinical trials were high, as evidenced by the pooled
ER estimate for mortality. Moreover, analysis of RCTs
resulted in a non-significant difference in the relative
risk for death between the treatment and control groups.
The high mortality rates in the studies included in our
analysis can be attributed to the high risk for mortality
characteristic of refractory shock despite proper treat-
ment [4]. However, our results indicate that a very large
Fig. 2 The risk ratio for mortality in randomized controlled trials (RCTs). The forest plot demonstrates point estimates of risk ratio surrounded by
95% confidence interval (CI). AVP arginine-vasopressin, TP terlipressin
Fig. 3 Event rate for mortality in all clinical trials. The plot demonstrates point estimates of event rates surrounded by 95% confidence interval (CI).
ER event rate
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number of patients would be necessary to reach the in-
formation size required to reach the futility boundaries
for mortality, as shown by TSA.
AVP acts on V1 receptors located on vascular smooth
muscle leading to vasoconstriction, and therefore ther-
apy with AVP/TP may put the patients at a higher risk
for developing tissue ischemia [9]. In adults, RCTs showed
a trend towards developing tissue ischemia with AVP/TP
therapy [35, 36]. Our meta-analysis found high event rates
for tissue ischemia among AVP/TP-treated patients.
The vasoactive score has previously been shown to be
associated with morbidity and mortality in PICUs [37, 38],
Fig. 4 Trial sequential analysis for mortality in randomized controlled trials: a relative risk of 1.01, two-sided boundary, incidence of 14.2% in the
control arm, incidence of 25.5% in the treatment arm, a low bias estimated relative risk reduction of 80%, α of 5%, power of 80% were set. There
is an estimated required information size of 392 randomized patients that are not reached. The boundaries for futility are not crossed and no
effect on mortality is observed; the z-curve is parallel to the boundary of the treatment group. AVP arginine-vasopressin, TP terlipressin
Fig. 5 The risk ratio for tissue ischemia in randomized controlled trials (RCTs). The forest plot demonstrates point estimates of risk ratio
surrounded by 95% confidence interval (CI). AVP arginine-vasopressin, TP terlipressin
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and also has been associated with improvement in length
of stay in the PICU [38]. Although AVP/TP treatment re-
sulted in lower vasoactive scores, it did not significantly
reduce clinically important outcomes such as mortality
and the length of stay in the PICU.
Our analysis found a significant increase in MAP and
a decrease in HR, in line with previous reports. These ef-
fects may be attributed to the mechanism by which
AVP/TP causes vasoconstriction, and to the decreased
sensitivity of vascular smooth muscle to catecholamines
in refractory shock [37–39]. However, this did not seem
to translate into a meaningful improvement in clinically
significant outcomes.
Unfortunately, most of the studies included in our
meta-analysis did not address the mechanism of shock
and did not report on performing echocardiography dur-
ing the study period, and, consequently, may have in-
cluded patients with different mechanisms of shock. In
light of the absence of information regarding ventricular
function in most of the studies identified, and the fact
that the outcome of neonatal and pediatric shock relies
on ventricular function, we were unable to assess the re-
lationship between the mechanism of shock and goal of
treatment and the effectiveness of AVP/TP. As AVP and
TP do not possess inotropic properties they are far less
likely to be of use in states of shock where ventricular
dysfunction is present. Additionally, the meta-analysis
included studies with children of different ages. As
scarce high-quality literature exists regarding the use of
AVP/TP in neonates and children with refractory shock,
a separate statistical analysis for neonates and children
was not feasible. Our results are therefore limited by the
nature of the available studies, as there may be differ-
ence between neonates and older children, and between
different types of shock, regarding the mechanism of
shock compensation and drug doses, as well as the po-
tential for adverse effects. For example, the presence of
DIC in refractory shock is probably higher than less se-
vere types of shock, and AVP/TP is more likely to
provide benefit in vasodilatory shock compared to car-
diogenic shock [40].
Conclusion
The results of our analysis emphasize the lack of ob-
served benefit for AVP/TP in terms of mortality, as
well as a possible association with ischemic events.
While the data available on this topic are limited,
and the possibility of a small benefit cannot be ruled
out, our trial sequential analysis suggests that further
studies are unlikely to demonstrate an improvement
in mortality; however, more studies would be neces-
sary to demonstrate this conclusively. Additionally,
further studies of AVP/TP incorporating an evalu-
ation of the mechanism of shock could enhance our
understanding of the clinical utility of AVP/TP for
specific types of shock.
We believe these findings are quite important, as they
can both inform current practitioners as to the best
available evidence regarding the efficacy and safety of
these agents.
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